Communiqués EyePoint, Inc.

Actions

EYPT

US30233G2093

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
12,25 ^USD	-4,74%		+0,49%	-32,95%

30/07	EyePoint achève le recrutement pour ses essais de phase 3 sur l'oedème maculaire diabétique	MT
30/07	EyePoint achève le recrutement pour ses deux essais pivots de phase 3 sur le Duravyu dans le traitement de l'oedème maculaire diabétique	CI

Communiqués

30/07	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)	AQ
16/07	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
13/07	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer	AQ
16/06	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
19/05	EyePoint Announces Participation at Upcoming Investor Conferences	AQ
18/05	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
14/05	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data	AQ
06/05	EyePoint: Q1 Earnings Snapshot	AQ
06/05	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments	AQ
29/04	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026	AQ
16/04	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
16/03	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
04/03	EyePoint: Q4 Earnings Snapshot	AQ
04/03	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments	AQ
02/03	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema	AQ
25/02	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026	AQ
24/02	EyePoint Announces Participation at Upcoming Investor Conferences	AQ
18/02	EyePoint Appoints Michael Campbell as Chief Commercial Officer	AQ
17/02	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
05/02	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026	AQ
16/01	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
07/01	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026	AQ
17/12	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
16/12	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
19/11	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration	AQ